C¹⁷ Research Network

The C¹⁷ Research Network operates under the auspices of the C¹⁷ Council, a non-profit organization that represents the 16 academic pediatric oncology/hematology programs in the 17 centres across Canada. The network is set up to encourage and develop collaborative, multi-disciplinary, multi-site, Canadian research in pediatric hematology, oncology and hematological stem cell transplantation in furthering C¹⁷’s mission to improve health outcomes and quality of life for children and adolescents in Canada with cancer and blood disorders.

C¹⁷ Research Network Operating Grant Competition

The C¹⁷ Research Network holds an annual peer-reviewed grant competition to fund projects in pediatric hematology, oncology and hematological stem cell transplantation. The grant review process ranks applications based on criteria including clear statement of research, methodology, innovativeness and originality, evidence of collaboration and multidisciplinary approach and impact or application into clinical practice. The scope of projects considered include but are not limited to: phase I, II, III and pilot clinical trials; registries and population based studies; biological sample banks; quality of life and psychosocial research; health outcomes and health service research; and basic laboratory and translational research. Note that applications are welcome for projects with a justification to function as a single centre, although collaboration is strongly encouraged. New collaborations, mentorship and applications from Young Investigators also are encouraged.

By encouraging and funding multi-centre, multi-disciplinary research Canada wide, C¹⁷ is reducing barriers to access to research studies and thereby increasing treatment and research opportunities for all children to participate in the improving of health outcomes and the quality of life. Funding for the competition is partnered with Childhood Cancer Canada and The Kids With Cancer Society (Edmonton).

The 100% Fund 

Nearly one in five children diagnosed with cancer will not survive. For children with rare and hard to treat cancers, the odds can be far worse. The 100% Fund has been created to challenge these odds. Phoebe Rose Rocks, Fight Like Mason, Melia’s Memory, Team Finn, Eli's Childhood Cancer Foundation, AnnFrances Tropea Foundation, Kindred Foundation and Childhood Cancer Canada have partnered to fund  research for children and teens who do not, yet, have their cure.

The 100% Fund targets pediatric and adolescent cancers that are hard to treat — cancers that have not responded to available therapies. The goal is to fund research with the potential to deliver improved treatment and increased survival rates.

See the Research Grants page for previously funded grants.

The 100% Fund Grant Competition (Round 4a, 2023) - EXTENDED DEADLINES!

The 100% Fund targets pediatric and adolescent cancers that are hard to treat — cancers that have not responded to available therapies. The goal is to fund research with the potential to deliver improved treatment and increased survival rates.

We will accept one application addressing Infant Leukemia in consideration of the Round 4a 2023 grant competition.

This call for Infant Leukemia grant applications is part of the larger 100% Fund Grant Competition that is also funding research in
Rhabdomyosarcoma and Osteosarcoma (Round 4).

Guidance Documents and Application Forms for the 100% Fund Grant Competition (Round 4a)

• 100% Fund Grant Call for Applications and Instructions
• 100% Fund Grant Application Form 
• C17 Grant Application Instructions and Award Guide (ver 01May2023)

*EXTENDED* Deadlines:

• Registration by email: Wednesday JANUARY 3, 2024
• Grant Submission: Wednesday JANUARY 24, 2024

Questions & Registration: evani.goll@c17.ca

For further information on the C¹⁷ Research Network contact: